Director/PDMR Shareholding

By

Regulatory News | 10 May, 2024

Updated : 17:08

RNS Number : 0518O
Judges Scientific PLC
10 May 2024
 

Judges Scientific plc

Director/PDMR Shareholding

In accordance with notification obligations under article 19.3 of the Market Abuse Regulation, the Company announces that on 9 May 2024 David Cicurel, CEO,  transferred the beneficial interest in 4,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares") to the Shoftim Charitable Trust (the "Charity").

David Cicurel is a trustee of the Charity. Following this gift David Cicurel is beneficially interested in 644,333 Ordinary Shares and he remains beneficially and non beneficially interested in 711,333 Ordinary Shares, his non beneficial interest comprising 67,000 Ordinary Shares he has gifted to the Charity .

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Cicurel

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Judges Scientific plc

b)

 

LEI

 

 

2138004EXWWPTW1JOL31

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares in Judges Scientific plc

 

 

GB0032398678

 

b)

 

Nature of the transaction

 

 

Gift beneficial interest in 4000 Ordinary Shares to the Charity

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£117.50

4,000

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A (single transaction)

e)

 

Date of the transaction

 

 

9/05/2024

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

-      For further information please contact:

 

 

 

Judges Scientific plc

David Cicurel, CEO

Brad Ormsby, CFO

Tel: +44 (0) 20 3829 6970

 

 

Shore Capital (Nominated Adviser & Joint Broker)

Stephane Auton

Harry Davies-Ball

Tel: +44 (0) 20 7408 4090

 


Liberum (Joint Broker)

Edward Mansfield

Nikhil Varghese

Tel : +44 (0) 20 3100 2222

 

 

Investec Bank plc (Joint Broker)

Virginia Bull

Carlton Nelson

Tel: +44 (0) 207 597 4000


Alma PR (Financial Public Relations)

Sam Modlin

Rebecca Sanders-Hewitt

Joe Pederzolli

Tel: +44 (0) 20 3405 0205

judges@almastrategic.co.uk



 

Notes to editors:

Judges Scientific plc (AIM: JDG), is a group focused on acquiring and developing companies in the scientific instrument sector. The Group now consists of 23 businesses acquired since 2005.

 

The acquired companies are primarily UK-based with products sold worldwide to a diverse range of markets including: higher education institutions, scientific research facilities, manufacturers and regulatory authorities. The UK is a recognised centre of excellence for scientific instruments. The Group has received five Queen's Awards for innovation and export.

 

The Group's companies predominantly operate in global niche markets, with long term growth fundamentals and resilient margins.

 

Judges Scientific maintains a policy of selectively acquiring businesses that generate sustainable profits and cash. Shareholder returns are created through the reduction of debt, organic growth and dividends.

 

For further information, please visit www.judges.uk.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBLGDUUGBDGSG

Last news